Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 10, 2021

View Archived Issues

HDAC6 linked to higher risk of relapse in HER2-positive breast cancer treated with trastuzumab

Shanghai Institutes for Biological Sciences presents islet-like cell clusters

iNtRON Biotechnology patents Myoviridae bacteriophage compositions

New BRD4 BD2 inhibitors discovered at Betta Pharmaceuticals

Medshine Discovery identifies new CCR5/CCR1 antagonists

Beijing Findcure Biosciences divulges tyrosine-protein kinase receptor UFO inhibitors

NCC-1566 demonstrates synergistic effect with levetiracetam in pharmacoresistant 6 Hz model

Stomach organoid created from multiple stem cell types

Mdm2 gene amplification is associated with poor outcome of patients with luminal breast cancer

lncRNA XIST could be used to select triple-negative breast cancer patients for ERbeta therapy

MDX-124 shows efficacy in preclinical models of TNBC

BetterLife's TD-0148A reverses depressive-like behavior in chronically stressed mice

Totus receives financing to advance TOS-358 drug program for cancer

CRISPR-Cas9 gRNA system eliminates diverse proviral HIV-1 strains

NextVivo launches to develop immune organoid technology platform

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 8, 2026.
New York University identifies new analogues of mannose-6-phosphate
BioWorld Science
New York University has discovered new analogues of mannose-6-phosphate reported to be potentially useful for the treatment of memory impairment,...
ASCO 2026: Chinese biopharma arrives at ASCO with pivotal wins
BioWorld
If the 2026 American Society of Clinical Oncology (ASCO) annual meeting in Chicago from May 30 to June 3 demonstrated anything about the evolution of China’s...
Bial-Portela discovers new OX1 receptor antagonists
BioWorld Science
Bial-Portela & Ca SA has patented new orexin OX1 receptor antagonists potentially useful for the treatment of anxiety disorders, depression, eating disorders,...
Autobahn on the fast track with bipolar thyroid agonist
BioWorld
Achieving high marks in the phase II Amplify-BD trial for bipolar I and II depression, Autobahn Therapeutics Inc.’s elunetirom, a brain-penetrant central nervous...